Metabolic network analysis reveals altered bile acid synthesis and cholesterol metabolism in Alzheimer's Disease

Priyanka Baloni[1], Cory C. Funk[1], Jingwen Yan[2], James T. Yurkovich[1], Alexandra Kueider-Paisley[3], Kwangsik Nho[2], Almut Heinken[4], Wei Jia[5], Siamak Mahmoudiandehkordi[3], Gregory Louie[3], Andrew J. Saykin[2], Matthias Arnold[6], Gabi Kastenmüller[6], William J Griffiths[7], Ines Thiele[4,8], The Alzheimer's Disease Metabolomics Consortium, Rima Kaddurah-Daouk[3]*, Nathan D. Price[1]*

[1] Institute for Systems Biology, Seattle, WA 98109
[2] Indiana Alzheimer Disease Center and Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN, USA
[3] Department of Psychiatry and Behavioral Medicine, Duke Institute for Brain Sciences, Duke University, Durham, NC 27708, USA
[4] School of Medicine, National University of Ireland, Galway, Ireland
[5] Cancer Biology Program, The University of Hawaii Cancer Center, Honolulu, HI, USA
[6] Institute of Bioinformatics and Systems Biology, Helmholtz Zentrum München - German Research Center for Environmental Health, Neuherberg, Germany
[7] Swansea University Medical School, ILS1 Building, Singleton Park, Swansea SA2 8PP, UK
[8] Discipline of Microbiology, School of Natural Sciences, National University of Ireland, Galway, Ireland

*To whom correspondence should be addressed: rima.kaddurahdaouk@duke.edu or nathan.price@systemsbiology.org

Lead contact: Nathan D. Price (nathan.price@systemsbiology.org)

Summary

Alzheimer's disease (AD) is the leading cause of dementia, with metabolic dysfunction seen years before the emergence of clinical symptoms. Increasing evidence suggests a role for primary and secondary bile acids, the end-product of cholesterol metabolism, influencing pathophysiology in AD. In this study, we analyzed transcriptomes from 2114 post-mortem brain samples from three independent cohorts and identified that the genes involved in the alternative bile acid synthesis pathway were expressed in the brain compared to the classical pathway. These results were supported by targeted

1

metabolomic analysis of primary and secondary bile acids measured from post-mortem brain samples of 111 individuals. We reconstructed brain region-specific metabolic networks using data from three independent cohorts to assess the role of bile acid metabolism in AD pathophysiology. Our metabolic network analysis suggested that taurine transport, bile acid synthesis and cholesterol metabolism differed in AD and cognitively normal individuals. Using the brain transcriptional regulatory network, we identified putative transcription factors regulating these metabolic genes and influencing altered metabolism in AD. Intriguingly, we find bile acids from the brain metabolomics whose synthesis cannot be explained by enzymes we find in the brain, suggesting they may originate from an external source such as the gut microbiome. These findings motivate further research into bile acid metabolism and transport in AD to elucidate their possible connection to cognitive decline.

Keywords

Alzheimer's disease, bile acids, cholesterol metabolism, transcriptomics, metabolomics, genome-scale metabolic models, transcriptional regulatory networks

Introduction

Alzheimer's disease (AD), the leading cause of dementia, is a progressive, multifactorial disease[1,2] where the onset and progression of symptoms varies significantly among individuals. Recent studies have shown that metabolic dysfunction is one of the factors associated with neurodegenerative disorders[3,4]. Various physiological processes such as lipid metabolism, immune function, amyloid precursor protein metabolism, oxidative

stress, neurotransmitter function as well as mitochondrial functions are altered in AD that can affect metabolism[5,6,7]. Interest in the transport of biochemical compounds between the brain and the gut and their possible role in regulating metabolic changes centrally and peripherally has increased recently across several neurodegenerative diseases[8,9]. There is increasing evidence to suggest a role in AD for primary and secondary bile acids[7,10,11]. Bile acids are amphipathic molecules and primary bile acids are derived from cholesterol mostly in the liver, whereas secondary bile acids are typically produced by bacteria in the gut[12]. Increased levels of secondary bile acids and ratios to their primary bile acid educts have been linked to AD and cognitive decline[7].

Cholesterol metabolism and transport have been studied extensively and are clearly linked with AD[13,1,14]. Cholesterol clearance leads to production of bile acids that carry out lipid absorption, cholesterol homeostasis and also function as signaling molecules[15]. Primary bile acids such as cholic acid and chenodeoxycholic acid are synthesized as a result of cholesterol efflux and then conjugated with glycine or taurine for secretion into bile and later metabolized by gut bacteria[12]. There are two major bile acid biosynthetic pathways: the classical pathway (neutral pathway) and the alternative pathway (acidic pathway). The classical pathway in mammalian liver is initiated by cholesterol 7α-hydroxylase (*CYP7A1)* and subsequently requires 12α-hydroxylase (*CYP8B1*) amongst numerous other enzymes for synthesis of cholic acid, whereas chenodeoxycholic acid is produced in the absence of *CYP8B1*[16]. Sterol 27-hydroxylase (*CYP27A1*) is required for the initiation of alternative bile acid pathway[17]. In the brain, sterol 24-hydroxylase (*CYP46A1*) converts cholesterol to 24S-hydroxycholesterol (systematic name cholest-5-

en-3β,24S-diol), and subsequent 7α-hydroxylation is carried out by 24-hydroxycholesterol 7α-hydroxylase (*CYP39A1*)[18] (Figure 1). Studies in human and mouse brain samples, as well as cell lines have shown that bile acids can cross the blood-brain barrier and bind to nuclear receptors, causing physiological changes[19,20]. There is limited information on the role of bile acids in the human brain and their association with cognitive decline in AD pathophysiology. Systematic analysis of omics data derived from blood and post-mortem brain samples of AD and cognitively normal (CN) or control individuals has the potential to identify differences in cholesterol and bile acid metabolism and how they contribute to AD pathogenesis.

In this study, we analyzed a large number of transcriptome data from the Religious Orders Study and Memory and Aging Project (ROSMAP), Mayo Clinic and the Mount Sinai Brain Bank that had a total of 2114 post-mortem brain samples from seven different brain regions. We reconstructed metabolic networks using the data from these three cohorts and studied the role of circulating bile acids that may contribute to AD and altered cholesterol metabolism in these individuals. We also generated targeted metabolomics data of primary and secondary bile acids from post-mortem brain samples of 111 AD patients and controls.

Various genomic studies have reported transcriptional regulatory changes in neurodegenerative diseases[21,22]. The biological significance of these transcription factors (TFs) regulating metabolic changes is not completely understood. The brain-specific metabolic and transcriptional regulatory networks proved useful in identifying

4

candidate metabolites and genes involved in the disease manifestation. A schematic representation of the study is represented in Figure 1. Our study used the following approaches to investigate the role of bile acids in AD:

(i)   Transcriptional profiling of genes that are involved in cholesterol and bile acid metabolism using publicly available data from post-mortem brain samples.

(ii)   Reconstruction and analysis of genome-scale metabolic networks of various brain regions to identify genes and reactions that are significant in AD vs CN.

(iii) Transcriptional regulatory network analysis of brain samples to predict candidate TFs regulating metabolically important genes.

In summary, our study addresses an important need to better understand potential roles for bile acids in AD pathophysiology.

Results

In recent studies, cytotoxic and neuroprotective bile acids were identified in AD and their probable link to cognitive decline in the individuals was reported[7,23]. To further investigate the role of primary and secondary bile acids in AD and CN individuals, we analyzed 2114 post-mortem brain samples from three independent cohorts for seven brain regions (Table 1) and selected genes involved in cholesterol and bile acid metabolism.

Table 1: Details of brain region-specific samples from three different cohorts. The total number of post-mortem brain samples for different regions, method of preparation of

5

RNA-sequencing library preparation, number of samples for different pathologies, gender and APOE status of the individuals is described in the table.

In this study, we studied the role of bile acids in AD pathology in the context of genome-scale metabolic and transcriptional regulatory networks (Figure 1).

Figure 1: *Graphical overview of analyses described herein to study altered cholesterol and bile acid metabolism in AD. Numbers of samples from each brain region are indicated along with AD and control samples and Male/Female breakdown in parentheses. We used the post-mortem brain sample transcriptome data to generate region-specific metabolic networks. We used these networks to study bile acid and cholesterol metabolism. Using the brain transcriptional regulatory network, we identified transcription factors that regulate genes in cholesterol and bile acid metabolism.*

Transcriptomic analysis of enzyme-encoding genes associated with bile acid metabolism

Bile acids are products of cholesterol metabolism. To identify cholesterol and bile acid genes that are expressed in the brain, we curated a list of regulators, transporters and biosynthesis genes in these three independent cohorts. Cholesterol biosynthesis regulators *SREBF1* and *SREBF2* were expressed in post-mortem brain samples and recent studies have identified variants of SREBP2, the protein encoded by *SREBF2*, and their probable link with AD[14,24,25]. Expression of genes involved in cholesterol transport *ABCA1, ABCA5, ABCA7, APOE, LPL* and *LCAT* and members of the LDLR gene family (*LDLR, VLDLR, LRP1, LRP2, LRP4, LRP5, LRP6, LRP8, LRAD3*) in the brain samples suggests active transport of cholesterol and cholesterol homeostasis in brain (Figure 2). *ABCA7*, a cholesterol transporter, belonging to the class of ATP-binding cassette transporters that has been identified as a risk factor for late-onset of AD[17], is not found in the existing KEGG pathways and was manually curated into our models. *ABCA7* was found to be expressed in the post-mortem brain samples. We also probed into genes encoding for receptors linked with the classical and alternative bile acid pathway and found expression of *PPARA, PPARG, LXRα/®, RAR* and RXRs (*RXRA, RXRB, RXRG*) in the samples but no evidence of expression of FXR.

Figure 2: *Heatmap for genes involved in (a) cholesterol and (b) bile acid metabolism. The color gradient is based on ubiquity score calculated for the genes and gray color represents genes having no expression data on the brain regions from three cohorts. Brain regions represented in the plot are cerebellum (CER), prefrontal cortex (FC), temporal cortex (TC), frontal pole (FP), inferior frontal gyrus (IFG), parahippocampal gyrus (PHG) and superior temporal gyrus (STG). The function of genes is indicated on the left side of each heatmap.*

We observed consistent expression of *CYP27A1* and *CYP7B1*, which are involved in the initial steps of the alternative bile acid pathway depicted in Figure 3, from the analysis of transcriptomic data of post-mortem brain samples from three independent

cohorts (Supplementary file 1). In the figure, the bile acids have been marked as cytotoxic and neuroprotective[7,23], but all bile acids become toxic at elevated concentrations because of their ability to solubilize membranes[23]. We did not observe expression of *CYP7A1* and *CYP8B1*, suggesting that the classical bile acid biosynthesis pathway is not prevalent in the brain samples. The classical pathway is known to be most active in the liver[26]. It has been reported that neural cholesterol clearance through bile acid synthesis is mediated by *CYP46A1* and subsequently by *CYP39A1* in the liver, leading to synthesis of chenodeoxycholic acid[27]. In addition to genes involved in the alternative bile acid pathway, we also observed expression of brain-specific *CYP46A1* and *CYP39A1* genes in all the cohorts. This analysis suggested that the brain utilizes an alternative and neural cholesterol clearance pathway of bile acid synthesis[27,11] and not the classical pathway[23].

Figure 3: *Schematic representation of bile acid synthesis pathway in humans. The order of enzymatic reactions can vary. Genes expressed in brain samples from our analysis are highlighted in pink. Based on the results from[7], bile acids have been marked as neuroprotective or cytotoxic.*

Metabolomics analysis of post-mortem brain samples to identify levels of primary and secondary bile acids

Bile acids were quantified from 111 post-mortem brain samples from the dorsolateral prefrontal cortex of AD, MCI and CN individuals in the ROSMAP study (https://www.synapse.org/#!Synapse:syn10235594) (Supplementary file 2). Although the genes involved in production of cholic acid were not expressed in the brain samples, detection of cholic acid from the metabolomics analysis suggested that cholic acid might enter the brain from the periphery as previously shown in other studies[20,28,29]. We compared the levels of primary and secondary bile acids in individuals with CERAD score of 1-4, where 1, 2, 3 and 4 indicate definitive AD, probable AD, possible AD and no evidence of AD, respectively. The ratio of primary conjugated and secondary bile acids with respect to cholic acid (CA) showed that deoxycholic acid (DCA), lithocholic acid (LCA), glycochenodeoxycholate (GCDCA), chenodeoxycholic acid (CDCA), taurodeoxycholic acid (TDCA), glycodeoxycholic acid (GDCA), ursodeoxycholic acid (UDCA), allolithocholate (alloLCA) and taurocholic acid (TCA) were higher in individuals with AD (CERAD score 1-3) compared to controls (Figure 4). Similar results were reported in the serum metabolomics samples of AD and CN individuals[7,10]. Allo-cholic acid (ACA) is a steroid bile acid has been studied in the context of signaling mechanisms related to differentiation, proliferation or apoptosis of hepatocytes[30]. The CDCA:CA ratio was calculated and it showed a higher value for AD compared to CN individuals in the study (Supplementary file 3). This finding suggests that the alternative bile acid pathway is more active in AD versus CN individuals. Also, the higher ratio of primary bile acid like TCA and secondary bile acids such as DCA, LCA, TDCA and GDCA in AD individuals indicated that these bile acids may be associated with cognitive function.

Figure 4: *Bar plots representing ratio of bile acids with respect to cholic acid (primary bile acid) measured from 111 brain samples from ROSMAP study. Blue bars represent AD samples and light orange bars represent control samples.*

The primary BAs are conjugated with glycine or taurine for secretion into bile[17]. In addition to the primary and secondary BAs, we also measured levels of taurine in serum samples in AD and CN individuals. In the serum, we observed that AD patients had higher levels of serum taurine compared to controls. Taurine is required for conjugation of primary and secondary bile acids. This is an interesting observation and we need to explore the transport and physiological levels of taurine in the brains of individuals with AD.

Metabolic reconstruction of brain regions and pathway-level analysis

We reconstructed metabolic networks for brain region-specific samples in the three independent cohorts. The seven brain regions in this study included cerebellum (CER), prefrontal cortex (FC), temporal cortex (TC), frontal pore (FP), inferior frontal gyrus (IFG), parahippocampal gyrus (PHG) and superior temporal gyrus (STG). We used transcriptome data from post-mortem brain samples for reconstructing metabolic networks (see Methods for more details). The brain region-specific metabolic networks consisted of ~5600-6300 reactions, 2800-4000 metabolites and each model had genes varying from 1500-1757 in these networks. Supplementary Figure 1a provides information of the numbers of reactions, metabolites and genes present in each of the brain region-specific networks and Supplementary Figure 1b compares the gene content overlaps across each of these networks. We have made the detailed content of all of these models available to the scientific community (Supplementary file 4-10).

We tested each model using 16 brain-specific in silico tests meant to mimic experimental evidence of metabolic functions in the brain ('metabolic tasks') (Supplementary file 11), that were obtained from a recently published work on human reconstruction[31]. These metabolic tasks represent a set of reactions that are brain-specific, and the metabolic networks generated passed 65-85% of the tasks (see Methods section). The metabolic tasks are listed in Supplementary file 11 and the models have been provided in SBML in Supplementary file 12-18. In addition to

14

generating brain region-specific metabolic networks, we also used the transcriptome data of 2114 post-mortem brain samples and obtained personalized networks for each sample in the study. Out of 2114 brain samples, 818 samples corresponded to individuals with AD, 138 possible AD, 137 probable AD and 617 controls. The dataset also consisted of 12 samples from other dementias, 163 samples with progressive supranuclear palsy, 58 samples with pathologic aging and 2 samples that were uncharacterized. From our metabolic networks, we identified 518 reactions that were involved in cholesterol metabolism, bile acid synthesis and transport of bile acids between different compartments in the metabolic networks. The personalized metabolic networks had distinct set of bile acid reactions active in the brain regions (details in the Methods section). Since the post-mortem brain samples for the brain regions were collected by three independent cohorts having different sequencing protocols and depth, the flux results were analyzed separately for these cohorts. The data suggest that the cerebellum and temporal cortex have similar sets of bile acid reactions that can be active in the personalized metabolic networks (Figure 5).

Figure 5: Clustergram for 518 reactions involved in bile acid metabolism in (a) Mayo clinic cohort (cerebellum and temporal cortex), (b) ROSMAP cohort (frontal cortex) and (c) Mount Sinai Brain Bank (frontal pole, inferior temporal gyrus, superior temporal gyrus and parahippocampal gyrus). The rows correspond to bile acid reactions in the network and the columns are colored based on the brain regions.

We analyzed the reaction fluxes and found a similar set of bile acid reactions carrying fluxes in metabolic networks of these independent cohorts. We used this information to carry out statistical analysis and identify reactions that are significantly different (p-value < 0.05) in brain regions of AD versus the CN individuals as well as identify reactions that were significant in males versus females with AD. We found reactions carrying out transport of taurine and cholesterol were significant in the dorsolateral prefrontal cortex, temporal cortex and parahippocampal gyrus. Taurine is an abundant amino acid present at roughly 1.2 mM in brain[32]. *SLC6A6* (*TAUT*) and *SLC36A1* (*PAT1*) function as

taurine transporters and increased transport of taurine across the blood brain barrier (BBB) has been reported for oxidative stress conditions[33]. We found expression of both these genes in the brain transcriptome dataset, suggesting that these genes are expressed in the brain and involved in transport of taurine. Table 2 provides details for significant bile acid reactions in brain regions identified from our analysis.

Table 2: *List of bile acid reactions from our metabolic analysis of brain regions. The reactions are represented in their VMH IDs and information related to the genes and subsystems are also shown in the table. P-values calculated by Fisher's exact test are indicated in the table and only those reactions with p-value < 0.05 are represented here.*

Reaction (VMH ID)	Genes associated	Subsystem	p-value
Frontal cortex			
AKR1C41	AKR1C4	Bile acid synthesis	0.033
r2505	ABCC1	Transport, endoplasmic reticular	0.030
r2146	SLCO1A2	Transport, extracellular	0.023
TAUBETAtc	SLC6A6	Transport, extracellular	0.009
Temporal cortex			
HMR_1685	CYP27A1	Bile acid synthesis	0.0067

CHSTEROLt	ABCA1, ABCG5, ABCG8	Transport, extracellular	0.0073
TAUPAT1c	SLC36A1	Transport, extracellular	0.0165
TCHOLABCtc	ABCA8	Transport, extracellular	0.0324
3DHCDCHOLt2	SLC10A1, SLC10A2	Transport, extracellular	0.0185
EBP1r	EBP	Cholesterol metabolism	0.0433
HMGLx	HMGCL	Cholesterol metabolism	0.0293
DHCR241r	DHCR24	Cholesterol metabolism	0.0413
EBP2r	EBP	Cholesterol metabolism	0.0277

PHG

HSD3B7P	HSD3B7	Bile acid synthesis	0.003
r1051		Transport, endoplasmic reticular	0.047
r1052		Transport, lysosomal	0.047
r2146	SLCO1A2	Transport, extracellular	0.009
RE1796R	HSD3B1, HSD3B2	Bile acid synthesis	0.003
TAUPAT1c	SLC36A1	Transport, extracellular	0.015

From our analysis, we identified reactions with *CYP27A1*, required by both the neural cholesterol clearance pathway and the alternative bile acid pathway, as being significant in AD versus CN brains. Other than bile acid synthesis, reactions involving metabolites such as 7a-hydroxycholesterol (Virtual Metabolic Human (VMH, www.vmh.life, REF ID: xol7a), 7a-hydroxy-5b-cholestan-3-one (VMH ID: xol7ah), 3a,7a-dihydroxy-5b-cholestane (VMH ID: xol7ah2) and 7a-hydroxy-cholestene-3-one (VMH ID: xol7aone) were also identified as being significantly different between AD and CN (p-values for these reactions reported in Table 2). Transport of bile acids such as taurolithocholic acid 3-sulfate (VMH ID: HC02198), ursodeoxycholic acid (VMH ID: HC02194), taurocholic acid (VMH ID: tchola) and 3-dehydroxychenodeoxy cholic acid (VMH ID: 3dhchchol) can also be probed further to understand the role of these bile acids in AD. Thus, *in silico* analysis of brain region-specific metabolic models provides insights into reactions that may be involved in metabolic changes in AD that can be validated from experimental data.

Identifying transcriptional regulators responsible for altered metabolism in AD

Transcription factors are one important aspect of metabolic regulation that operate through adjusting the expression of enzyme-encoding genes. Using a transcriptional regulatory network informed from the same Mayo temporal cortex bulk RNA-seq samples used for the metabolic reconstruction, we identified candidate TFs that interact with metabolic genes in cholesterol and bile acid metabolism. We selectively studied those genes that belonged to reactions that were significantly differentially expressed in AD versus controls, in order to study their role in AD. For example, one gene that came

up from our metabolic analysis of AD and controls was emopamil binding protein (*EBP*) (Figure 6). *EBP* is involved in cholesterol metabolism as it is responsible for one of the final steps in the production of cholesterol. Our brain TRN analysis identified *POU6F2, IRF2, SMAD5, GABPA* and *TBR1* as the top candidate TF regulators for EBP. Regulation by these TFs can help in understanding their role in altered cholesterol metabolism in AD, particularly in evaluating the summation of coordinated changes since these TFs of course control other genes as well. *CYP27A1*, as mentioned earlier, is part of the alternative bile acid synthesis pathway and *CREB3L2* and *SOX8* are putative TFs that regulate expression of this gene. *CREB3L2* (cAMP-responsive element binding protein 3-like 2) is induced as a result of ER stress and may function in unfolded protein response signaling in neurons[34]. Other than the metabolism related genes, we also evaluated interactions of bile acid transporters such as *SLC6A6, SLCO1A2, ABCC1, ABCA1, SLC36A1, ABCA8* and their transcriptional regulation. As seen in Figure 6, *SREBF2* was found to interact with *ABCA1* and recently there were reports of variants of SREBP2 that have been linked with AD[25]. Increased *SREBF2* expression leads to higher cholesterol levels and presumably oxysterol and cholestenoic acid levels which are ligands of LXR. The peroxisome proliferator-activated receptors (PPARs) regulate various physiological processes and are expressed in the central nervous system. *PPARA* regulates genes involved in fatty acid metabolism and has been reported to regulate neuronal *ADAM10* expression, in turn affecting proteolysis of amyloid precursor protein[35]. *PPARA* was identified as a putative regulator of *ABCA1* in our brain transcriptional regulatory network. *ABCA1* plays a role in cholesterol metabolism and transport and is a candidate risk gene for late onset

Alzheimer's disease (LOAD)[36]. *SLC6A6*, involved in transport of taurine, was found to be putatively regulated by *STAT1*, a TF reported to play an important role in spatial learning and memory formation[37], and *RXRG*, that forms heterodimers with retinoic acid (RA), LXRs and vitamin D receptors (VDR) [38]. Neuronal differentiation 6 (*NEUROD6*) functions in neuronal development, differentiation, and survival in AD[39] . Regulation of *SLC36A1* by *NEUROD6* indicated that this TF plays a role in controlling transport of taurine in the brain. These interactions can be probed further to understand their role in AD pathophysiology.

Figure 6: *Transcriptional regulatory network of brain highlighting transcription factors and metabolic genes involved in cholesterol and bile acid metabolism. TFs are represented as blue triangles, bile acid metabolism genes as yellow circles and cholesterol metabolism genes as pink rectangles. The significant genes are highlighted*

with red border and transcription factors in darker shade of blue. Red edges represent

interactions between genes and TFs.

In summary, the brain transcriptional regulatory network analysis led to the identification

of candidate TFs that regulate genes in cholesterol and BA metabolism, providing clues

towards possible roles in bile acid dysregulation in AD.

Discussion

We carried out a systematic study to identify alterations in cholesterol and bile acid

metabolism in AD versus cognitively normal (CN) controls using patient-derived post-

mortem transcriptomics and metabolomics data. The primary findings of our study are:

(1) alternative and neural cholesterol clearance pathway of bile acid synthesis pathway

genes were expressed in the brain samples included in this study, indicating that these

pathways are prevalent in the brain as compared to the classical bile acid synthesis

pathway; (2) targeted metabolomics analysis of post-mortem brain samples identified

primary and secondary bile acids and higher ratio of GCDCA:CA and secondary bile

acids like DCA, LCA, TDCA, CDCA and GDCA in AD vs controls suggests that these

bile acids might be associated with cognitive decline in AD; (3) the presence of

secondary bile acids in metabolomics data suggests a possible role of gut microbiome

in AD and highlights the need to study the gut-brain axis to understand changes in AD;

(4) transporters associated with taurine and cholesterol metabolism showed different

usage based on our genome-scale metabolic network analysis of three independent

cohorts; and (5) transcriptional regulatory network analysis identified transcription

factors including *PPARA, RXRG* and *SREBF2* regulating bile acid and cholesterol genes in the brain.

Role of bile acids in AD pathophysiology and use of genome-scale metabolic models

Bile acids are derived from cholesterol and their synthesis is regulated by complex feedback mechanisms[12,18]. Recent studies have identified bile acids in brain samples and linked them with cognitive decline in AD[7,10,19]. To understand the physiological role of bile acids in the brain of AD and CN individuals, we analyzed transcriptome data from post-mortem brain samples obtained from three independent cohorts and identified genes involved in the alternative bile acid pathway were expressed compared to the classical pathway in the brain. The alternative bile acid pathway is initiated by *CYP27A1* that catalyzes the steroid side-chain oxidation and in the subsequent step forms C24-bile acids. It is also known that cholesterol is converted to 24-hydroxycholesterol by sterol 24-hydroxylase (*CYP46A1*) in the brain and the gene was found to be expressed in the brain samples. The primary bile acids conjugate with glycine and taurine to form secondary bile acids. Taurine has a neuroprotective role in the brain and bile acids conjugated with taurine are found to be present in the brain. Metabolomics data of serum samples showed AD patients had higher levels of serum taurine compared to controls, indicating taurine transport across the BBB might be affected in AD. The presence of secondary bile acids in the post-mortem brain samples suggests that these bile acids are either endogenously present in the brain or they are transported through the BBB. Bile acids such as ursodeoxycholic acid, taurocholic acid, taurolithocholic acid 3-sulfate and 3-dehydroxychenodeoxy cholic acid were also identified from our analysis and the role of these bile acids can be probed further. Based on an association study,

taurolithocholic acid was predicted to be a cytotoxic bile acid whereas chenodeoxycholic acid and ursodeoxycholic acid were predicted as neuroprotective bile acids[7]. Our analysis of transcriptome data of 2114 samples mapped into metabolic networks of brain regions implicated reactions involved in the production of metabolites such as 7〈-hydroxycholesterol, 7〈-hydroxy-5®-cholestan-3-one, 7〈-hydroxycholestene-3-one and other derivatives that are formed through *CYP7A1* being significantly different (p-values for these reactions reported in Table 2) between AD vs CN. Although *CYP7A1* was not expressed in the post-mortem brain samples, the difference in abundance of these metabolites in AD vs CN suggests that we should explore the possibility of these metabolites entering the brain through the periphery. In this study, we have used transcriptomic data that was available from three independent cohorts. Transcriptomics data is insufficient to parametrize the metabolic models, but if a denser longitudinal omics data becomes available in the future it will help in improvising the predictions from these *in silico* models. Although our analysis indicates reactions that are significant in these conditions, the directionality of the reactions can be solidly determined only if we have additional time-series metabolomics data (and ideally isotopic labeling experiments) to support these changes. Methods are now being developed to obtain cell type-specific data [40], [41]), so that we can gain additional information into the brain cells that are involved in regulating metabolic changes in AD. These studies have shown that microglia and neuronal cells had different transcriptional responses in AD versus control. Integrating such cell-specific data will help in refining the models and making more accurate predictions. Our brain-tissue metabolic models can be used by the community to capture *in silico* changes and possibly identify

metabolic biomarkers prior to disease manifestation, making them useful in understanding interactions and mechanisms between different classes of metabolites and AD pathophysiology.

Transcriptional regulation of bile acid and cholesterol genes

Metabolism is influenced by regulation of transcription factors and metabolic genes. In this study, we used a transcriptional regulatory network of brain (and selected brain regions) to identify candidate TFs that may interact with genes in cholesterol and bile acid metabolism. We identified *SREBF2, PPARA, RXRG* and other transcription factors, some of which have been studied and implicated in Alzheimer's disease. *SREBF2* expression enhances cholesterol levels[42] and presumably oxysterol and cholestenoic acid levels which are ligands of LXR[43]. LXRs and the genes regulated by LXRs such as *ABCA1, ABCG1* and *APOE*, modulate intracellular cholesterol content and cholesterol efflux and have been associated with AD pathogenesis[44]. Our analysis also identified *PPARA* as putative regulator of *ABCA1* and recent studies have demonstrated that PPAR pathway activation increased *ABCA1* levels, that in turn lead to APOE lipidation and amyloid ß clearance[45]. We also identified transport of taurine as an important factor from the metabolic analysis. *SLC6A6* (neurotransmitter transporter, taurine) and *SLC36A1* (neutral amino acid/proton symporter) play a role in taurine transport. Although there was a 1.02 to 1.3-fold change in the expression of these transporters in AD compared with control samples of the three cohorts across four tested brain regions, this difference was only found to be statistically significant in cerebellum (Supplementary file 1). Integration of expression data with metabolic network of brain

regions identified reactions involving taurine transporters that were statistically significant in AD versus controls, further supporting their potential role. We had also *STAT1* is a putative TF of *SLC6A6*, identified from our analysis of brain regulatory network. Studies have suggested that the increased *STAT1* may be involved in inflammation in AD brain[37,46]. *NEUROD6* regulates the activity of *SLC36A1*, a proton-coupled amino acid transporter. *NEUROD6* is a basic helix-loop-helix TF and SNPs in *NEUROD6* have been associated with AD, especially in APOE4+ women[47]. Our analysis has been able to capture metabolic genes and putative TFs that regulate them. These findings can be further strengthened by generation of higher quality footprint data from brain samples.

Studying the gut-brain axis to understand physiological changes in AD

Increasing evidence from experimental and clinical data suggests influence of gut-brain axis and gut microbiota in neurodegenerative diseases[48,49]. From our metabolic analysis we identified taurolithocholic, 3-dehydrochenodeoxycholic, and ursodeoxycholic acid, secondary bile acids, significant in AD compared to CN[50] suggesting a possible connection to the gut microbiome. Recently, the bile acid deconjugation and biotransformation pathways have been reconstructed in a resource of genome-scale reconstructions of over 800 human gut microbes[51,52]. Of these, only 23 species could synthesize 3-dehydrochenodeoxycholic acid, only four could synthesize lithocholic acid, and only three could synthesize ursodeoxycholic acid[52]. For instance, the species *Ruminococcus* (*Blautia*) gnavus, and *Collinsella aerofaciens* synthesize 3-dehydroxychenodeoxycholic and ursodeoxycholic acid, and *Eggerthella lenta*

27

synthesizes 3-dehydrochenodeoxycholic and several Clostridiales representatives synthesize lithocholic acid[52], indicating these species may play a role in Alzheimer's disease. Interestingly, increased lithocholic acid in plasma has recently been proposed as a potential biomarker for Alzheimer's disease[53]. Recent reports have shown influence of bile acids to host metabolism via alterations of the bacterial community structure[54]. The personalized brain models developed in this study could be joined with personalized microbial community models established previously[52,55]. In future efforts, such combined host-microbe metabolic modeling will yield more insight into mechanisms underlying altered bile acid metabolism in Alzheimer's disease.

STAR Methods

1. Transcriptome analysis of post-mortem brain samples

Transcriptome data was obtained from post-mortem brain samples of AD patients and cognitively normal individuals from Religious Orders Study and Memory and Aging Project (ROSMAP), Mayo Clinic, University of Florida, Institute for Systems Biology and Mount Sinai Brain Bank (MSBB). 265 samples of temporal cortex (TC) and cerebellum (CER), 632 samples of frontal cortex (FC), 303 samples of frontal pole (FP), superior temporal gyrus (STG), inferior frontal gyrus (IFG) and parahippocampal gyrus (PHG) with pathologies such as AD, MCI, Parkinson's and control were analyzed and used for construction of brain region-specific metabolic models. ROSMAP data can be requested via the Rush Alzheimer's Disease Center website (https://www.radc.rush.edu/). RNA-seq libraries were prepared by different methods such as poly-A enriched, strand-specific and ribo-zero. The RNAseq data from different centers were uniformly

processed using a consensus set of tools with only library type-specific parameters varying between pipelines. We have used these uniformly-processed data for analysis in our study. Table 1 has information of number of patients with various pathologies and controls and methods used for RNA-sequencing. The data used in the preparation of this article were downloaded from Synapse (https://www.synapse.org/#!Synapse:syn2580853/). We performed two-tailed t-test with Benjamini-Hochberg correction to identify differentially expressed genes with corresponding p-values. The differential expression analysis for transcriptome data from three independent cohorts is presented in Supplementary file 1.

2. Bile acid sample preparation and analysis

Participants of the Religious Orders Study (ROS) are comprised of Catholic brothers, nuns, and priests who were cognitively normal at study entry and agreed to annual clinical examinations and brain donation at time of death. The Rush Memory and Aging Project (MAP) is a companion study that includes community-dwelling older adults that all agreed to evaluations similar to ROS. Quantification of bile acid concentration was performed at the University of Hawaii cancer center. The bile acid-free matrix (BAFM) was used to prepare bile acid calibrators. Extracts of brain tissue along with bile acid reference standards were subjected to instrumental analysis[56,57]. All of the 57 bile acid standards were obtained from Steraloids Inc. (Newport, RI) and TRC Chemicals (Toronto, ON, Canada) and 9 stable isotope-labeled standards were obtained from C/D/N Isotopes Inc. (Quebec, Canada) and Steraloids Inc. (Newport, RI). A Waters ACQUITY ultra performance LC system coupled with a Waters XEVO TQ-S mass

spectrometer was used for all analyses. Chromatographic separations were performed with an ACQUITY BEH C18 column. UPLC-MS raw data obtained with negative mode were analyzed using TargetLynx™ applications manager to obtain calibration equations and the quantitative concentration (uM) of each bile acid. Bile acids were measured from the dorsolateral prefrontal cortex of 111 individuals with brain pathology (28, 33, 10, 22 and 18 with CERAD score of 1, 2, 3, 4 and 9 (missing), respectively). Metabolomics data can be accessed with permission at https://www.synapse.org/#!Synapse:syn10235594. We calculated the ratio of primary and secondary bile acids measured in metabolomics study and performed two-tailed t-test to calculate p-value for each bile acid.

3. Brain region-specific metabolic reconstruction

We used transcriptome data (https://www.synapse.org/#!Synapse:syn2580853/) derived from post-mortem brain samples of three independent cohorts: Mayo clinic, ROSMAP and Mount Sinai Brain Bank. These cohorts contained information of different brain regions (CER, FC, TC, FP, STG, IFG and PHG) and the data was used to generate brain region-specific metabolic networks. We converted the transcriptome data to binary by considering transcripts with expression values less than 25th percentile in the matrix as 0 otherwise 1. We calculated ubiquity scores for genes in each brain region separately and used those for implementing mCADRE workflow[58]. The ubiquity score of a gene is equal to the sum of samples in which the gene is expressed divided by the total number of samples. The Recon 3D model[31] of human metabolism was used as template to reconstruct brain region-specific metabolic networks as this model had

information of reactions related to the primary and conjugated primary acids additionally added to refine the model. The mCADRE workflow required two inputs to build region-specific metabolic models: (1) a global metabolic reconstruction, which in this case was the Recon 3D model, and (2) region-specific gene expression data from many individuals. Using the mCADRE workflow, we generated the draft reconstructions for each brain region. We used functions in COBRA toolbox such as detectDeadEnds to identify dead end metabolites and identifyBlockedRxns to compute all blocked reactions in the draft reconstructions. We used reactions from the Recon 3D model for filling gaps in the metabolic network. We carried out this step for each metabolic network reconstructed for brain regions. We also removed the reactions belonging to drug metabolism from the network as they were not related to functions in the brain. Only partial urea cycle is reported to be active in the brain, and so we identified enzymes in the urea cycle that are present in brain[59] and included the reactions related to these genes in the metabolic networks. We also included exchange reaction for metabolites identified in the cerebrospinal fluid (CSF) (by metabolomics data as well as the whole-body metabolism reconstruction[55] and metabolites that can be taken up across the blood brain barrier (BBB) from blood into the CSF[60,61,62,63,64,65]. The list of metabolites known to pass the BBB is provided in Supplementary file 19. Using the removeUnusedGenes function in the COBRA toolbox we removed genes that were not used in any reaction in the reconstructions. Then we carried out manual curation for genes present in the metabolic network using information from Human Protein Atlas[66] for genes expressed in the brain. This effort helped in providing further evidence for genes being present in the metabolic networks for brain regions. The information for

reactions, metabolites and genes in metabolic networks of brain regions is provided in Supplementary files 4-10. We tested our models for 16 metabolic tasks (Supplementary file 11) that are brain specific and the models passed 65-85% of those tests. As astrocytes are predominantly involved in maintaining brain physiology[67], we used objective function of astrocytes for our brain metabolic networks. We constrained bounds of exchange reactions using information from a published work on metabolic interactions between cell types in brain[68]. Details of metabolites involved in objective function and bounds for constrained reactions are given in Supplementary file 4-10. We integrated expression data with the brain region-specific metabolic networks and generated context-specific personalized metabolic networks for each sample in the study using iMAT algorithm[69]. Flux variability analysis[70] was carried out to evaluate minimum and maximum flux for each reaction in the metabolic networks. The codes used for reconstruction and model generation and simulation are provided in GitHub (https://github.com/PriceLab/Bile_acid_AD). We used COBRA toolbox v3.0[71] for metabolic analysis that was implemented in MATLAB R2018a and academic licenses of Gurobi optimizer v7.5 and IBM CPLEX v12.7.1 were used to solve LP and MILP problems.

4. *Reaction and pathway-level analysis*

We carried out flux variability analysis[70] for each context-specific personalized metabolic network and used the values for predicting metabolic changes in AD versus CN individuals and sex of the individuals. FVA results were used to generate a matrix in which reactions for which both minimum (vmin) and maximum (vmax) FVA flux are 0,

were considered to be non-active and assigned a state of 0, while the remaining reactions were assigned a state of 1. We carried out this analysis for all context-specific metabolic networks. Thus, our matrix contained binary values for all reactions in 2114 context-specific personalized metabolic networks for seven brain regions. We used this scheme to classify the reactions and obtain information not only on the basis of flux measurements but also their activity in each network. From all the reactions in the metabolic networks, we selected only those that belonged to cholesterol metabolism, bile acid synthesis and transport reactions associated with the bile acid metabolites. We applied Fisher's exact test on the binarized values of reactions to identify those reactions with p-value < 0.05 in AD versus CN. These reactions were identified as significant reactions in these groups.

5. *Metabolic regulatory network*

The transcriptional regulatory network analysis (TReNA) package (https://rdrr.io/bioc/TReNA/) was used for identifying transcription factors (TFs) that are part of the co-expression modules of interest. Brain-specific transcriptional regulatory network was constructed[72] using information from ENCODE. We downloaded the DNase Hypersensitivity (DHS) fastq files from ENCODE for all available brain samples and aligned the sequences using the SNAP method[73]. We performed two alignments using seed size of 16 and 20bp. The length of sequence data was >50 bp. The regions of open chromatin were identified using peak calling algorithm, F-Seq[74]. Footprints were generated using default parameters for Wellington[75] and HINT[76]. Our method generated individual gene models and those footprints that are within the proximal promoter region

(+/-5 kb of the transcription start site) are considered as priors in assessing the relationship between the expression of the TF and target genes. We prioritized putative TF regulators for each gene in the model using LASSO regression techniques, Pearson and Spearman correlation and random forest methods and projected the scores from these approaches into PCA space. The principal components were summed together to obtain a single composite score called pcaMax. This process is part of the trena package in Bioconductor (https://rdrr.io/bioc/TReNA/) and we applied the method to the post-mortem samples from temporal cortex from Mayo Clinic. We used metabolic genes identified from reaction-level analysis involved in bile acid and cholesterol metabolism and mapped top five transcription factors that interact with these metabolic genes and created an interaction network. This interaction networks gave information for transcription factors that regulate metabolic genes and are involved in significant reactions in AD versus cognitively normal individuals. Cytoscape 3.7.1[77] was used for visualizing the brain transcriptional regulatory network.

Supplemental Information

Supplementary figure 1 (a) provides information of the numbers of reactions, metabolites and genes present in each of the brain region-specific networks and (b) compares the gene content overlaps across each of these networks

Supplementary file 1: Analysis of transcriptomic data of post-mortem brain samples from three independent cohorts (excel file format).

Supplementary file 2: Bile acids measurements from 111 post-mortem brain samples from the dorsolateral prefrontal cortex of AD, MCI and CN individuals in the ROSMAP study (excel file format).

Supplementary file 3: Ratio of primary and secondary bile acids with respect to cholic acid (excel file format)

Supplementary file 4: Details of reactions and metabolites in Cerebellum metabolic network (excel file format).

Supplementary file 5: Details of reactions and metabolites in Frontal cortex metabolic network (excel file format).

Supplementary file 6: Details of reactions and metabolites in Temporal cortex metabolic network (excel file format).

Supplementary file 7: Details of reactions and metabolites in Frontal pole metabolic network (excel file format).

Supplementary file 8: Details of reactions and metabolites in Inferior Frontal gyrus metabolic network (excel file format).

Supplementary file 9: Details of reactions and metabolites in Parahippocampal gyrus metabolic network (excel file format).

Supplementary file 10: Details of reactions and metabolites in Superior Temporal gyrus metabolic network (excel file format).

Supplementary file 11: Details of metabolic tasks in brain (excel file format).

Supplementary file 12: Cerebellum metabolic network (xml format).

Supplementary file 13: Frontal cortex metabolic network (xml format).

Supplementary file 14: Temporal cortex metabolic network (xml format).

Supplementary file 15: Frontal pole metabolic network (xml format).

Supplementary file 16: Inferior Frontal gyrus metabolic network (xml format).

Supplementary file 17: Parahippocampal gyrus metabolic network (xml format).

Supplementary file 18: Superior Temporal gyrus metabolic network (xml format).

Supplementary file 19: List of metabolites that can cross blood brain barrier.

Data availability

Transcriptome data: https://www.synapse.org/#!Synapse:syn2580853/

Metabolomics data: https://www.synapse.org/#!Synapse:syn10235594

Code availability

The code used for reconstruction and model generation and simulation are provided in GitHub (https://github.com/PriceLab/Bile_acid_AD)

Acknowledgements

Authors contribution

NDP and RKD conceived and supervised the study. PB reconstructed the brain region-specific metabolic networks; PB, CF, and JY analyzed the transcriptomics data for post-mortem brain samples downloaded from the AMP-AD knowledge portal; AKP analyzed

the metabolomics data of brain; IT provided the list of metabolites that can cross blood-brain barrier; WJG provided valuable comments for bile acid analysis; WJ measured bile acids from post-mortem brain samples; AMP-AD consortium and the Alzheimer Disease Metabolomics Consortium collected transcriptomics and metabolomics data; PB, CF, JTY, JY, AKP, KN, AH, SM, GL, AJS, MA, GK, WJG, IT, RKD, and NDP contributed to the writing of this paper.

Declaration of Interests

The authors declare no competing interests.

References

1. Di Paolo G, Kim T-W. Linking lipids to Alzheimer's disease: cholesterol and beyond. Nat Rev Neurosci. 2011 May;12(5):284–96.

2. Vogel JW, Vachon-Presseau E, Pichet Binette A, Tam A, Orban P, La Joie R, et al. Brain properties predict proximity to symptom onset in sporadic Alzheimer's disease. Brain. 2018 Jun 1;141(6):1871–83.

3. Cai H, Cong W-N, Ji S, Rothman S, Maudsley S, Martin B. Metabolic dysfunction in Alzheimer's disease and related neurodegenerative disorders. Curr Alzheimer Res. 2012 Jan;9(1):5–17.

4. Mattson MP, Arumugam TV. Hallmarks of Brain Aging: Adaptive and Pathological Modification by Metabolic States. Cell Metab. 2018 Jun 5;27(6):1176–99.

5. Kaddurah-Daouk R, Zhu H, Sharma S, Bogdanov M, Rozen SG, Matson W, et al. Alterations in metabolic pathways and networks in Alzheimer's disease. Transl Psychiatry. 2013 Apr 9;3:e244.

6. International Genomics of Alzheimer's Disease Consortium (IGAP). Convergent genetic and expression data implicate immunity in Alzheimer's disease. Alzheimers Dement. 2015 Jun;11(6):658–71.

7. MahmoudianDehkordi S, Arnold M, Nho K, Ahmad S, Jia W, Xie G, et al. Altered bile acid profile associates with cognitive impairment in Alzheimer's disease-An emerging role for gut microbiome. Alzheimers Dement. 2019 Jan;15(1):76–92.

8. Ghaisas S, Maher J, Kanthasamy A. Gut microbiome in health and disease: Linking the microbiome-gut-brain axis and environmental factors in the pathogenesis of systemic and

neurodegenerative diseases. Pharmacol Ther. 2016 Feb;158:52–62.

9. Tremlett H, Bauer KC, Appel-Cresswell S, Finlay BB, Waubant E. The gut microbiome in human neurological disease: A review. Ann Neurol. 2017 Mar;81(3):369–82.

10. Nho K, Kueider-Paisley A, MahmoudianDehkordi S, Arnold M, Risacher SL, Louie G, et al. Altered bile acid profile in mild cognitive impairment and Alzheimer's disease: Relationship to neuroimaging and CSF biomarkers. Alzheimers Dement. 2019 Feb;15(2):232–44.

11. McMillin M, DeMorrow S. Effects of bile acids on neurological function and disease. FASEB J. 2016 Nov;30(11):3658–68.

12. Griffiths WJ, Sjövall J. Bile acids: analysis in biological fluids and tissues. J Lipid Res. 2010 Jan;51(1):23–41.

13. Martins IJ, Berger T, Sharman MJ, Verdile G, Fuller SJ, Martins RN. Cholesterol metabolism and transport in the pathogenesis of Alzheimer's disease. J Neurochem. 2009 Dec;111(6):1275–308.

14. Fonseca ACRG, Resende R, Oliveira CR, Pereira CMF. Cholesterol and statins in Alzheimer's disease: current controversies. Exp Neurol. 2010 Jun;223(2):282–93.

15. Houten SM, Watanabe M, Auwerx J. Endocrine functions of bile acids. EMBO J. 2006 Apr 5;25(7):1419–25.

16. Russell DW. The enzymes, regulation, and genetics of bile acid synthesis. Annu Rev Biochem. 2003 Jan 16;72:137–74.

17. Chiang JYL. Bile acid metabolism and signaling. Compr Physiol. 2013 Jul;3(3):1191–212.

18. Chiang JY. Recent advances in understanding bile acid homeostasis. F1000Res. 2017 Nov 20;6:2029.

19. Pan X, Elliott CT, McGuinness B, Passmore P, Kehoe PG, Hölscher C, et al. Metabolomic Profiling of Bile Acids in Clinical and Experimental Samples of Alzheimer's Disease. Metabolites [Internet]. 2017 Jun 17;7(2). Available from: http://dx.doi.org/10.3390/metabo7020028

20. Quinn M, McMillin M, Galindo C, Frampton G, Pae HY, DeMorrow S. Bile acids permeabilize the blood brain barrier after bile duct ligation in rats via Rac1-dependent mechanisms. Dig Liver Dis. 2014 Jun;46(6):527–34.

21. Ament SA, Pearl JR, Cantle JP, Bragg RM, Skene PJ, Coffey SR, et al. Transcriptional regulatory networks underlying gene expression changes in Huntington's disease. Mol Syst Biol. 2018 Mar 26;14(3):e7435.

22. Pearl JR, Colantuoni C, Bergey DE, Funk CC, Shannon P, Basu B, et al. Genome-Scale Transcriptional Regulatory Network Models of Psychiatric and Neurodegenerative Disorders. Cell Syst. 2019 Feb 27;8(2):122–35.e7.

23. Griffiths WJ, Abdel-Khalik J, Yutuc E, Roman G, Warner M, Gustafsson J-Å, et al. Concentrations of bile acid precursors in cerebrospinal fluid of Alzheimer's disease patients. Free Radic Biol Med. 2019 Apr;134:42–52.

24. Shah SA, Yoon GH, Chung SS, Abid MN, Kim TH, Lee HY, et al. Novel osmotin inhibits SREBP2 via the AdipoR1/AMPK/SIRT1 pathway to improve Alzheimer's disease neuropathological deficits [Internet]. Vol. 22, Molecular Psychiatry. 2017. p. 407–16. Available from: http://dx.doi.org/10.1038/mp.2016.23

25. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest. 2002 May;109(9):1125–31.

26. Björkhem I, Araya Z, Rudling M, Angelin B, Einarsson C, Wikvall K. Differences in the regulation of the classical and the alternative pathway for bile acid synthesis in human liver. No coordinate regulation of CYP7A1 and CYP27A1. J Biol Chem. 2002 Jul 26;277(30):26804–7.

27. Mertens KL, Kalsbeek A, Soeters MR, Eggink HM. Bile Acid Signaling Pathways from the Enterohepatic Circulation to the Central Nervous System. Front Neurosci. 2017 Nov 7;11:617.

28. DeMorrow S. Bile Acids in Hepatic Encephalopathy. J Clin Exp Hepatol. 2019 Jan;9(1):117–24.

29. Xie G, Wang X, Jiang R, Zhao A, Yan J, Zheng X, et al. Dysregulated bile acid signaling contributes to the neurological impairment in murine models of acute and chronic liver failure. EBioMedicine. 2018 Nov;37:294–306.

30. Mendoza ME, Monte MJ, Serrano MA, Pastor-Anglada M, Stieger B, Meier PJ, et al. Physiological characteristics of allo-cholic acid. J Lipid Res. 2003 Jan;44(1):84–92.

31. Brunk E, Sahoo S, Zielinski DC, Altunkaya A, Dräger A, Mih N, et al. Recon3D enables a three-dimensional view of gene variation in human metabolism. Nat Biotechnol. 2018 Mar;36(3):272–81.

32. Griffin JWD, Bradshaw PC. Amino Acid Catabolism in Alzheimer's Disease Brain: Friend or Foe? Oxid Med Cell Longev. 2017 Feb 5;2017:5472792.

33. Kang Y-S, Ohtsuki S, Takanaga H, Tomi M, Hosoya K-I, Terasaki T. Regulation of taurine transport at the blood-brain barrier by tumor necrosis factor-α, taurine and hypertonicity [Internet]. Vol. 83, Journal of Neurochemistry. 2002. p. 1188–95. Available from: http://dx.doi.org/10.1046/j.1471-4159.2002.01223.x

34. Kondo S, Saito A, Hino S-I, Murakami T, Ogata M, Kanemoto S, et al. BBF2H7, a novel transmembrane bZIP transcription factor, is a new type of endoplasmic reticulum stress transducer. Mol Cell Biol. 2007 Mar;27(5):1716–29.

35. Corbett GT, Gonzalez FJ, Pahan K. Activation of peroxisome proliferator-activated receptor α stimulates ADAM10-mediated proteolysis of APP. Proc Natl Acad Sci U S A. 2015 Jul 7;112(27):8445–50.

36. Lupton MK, Proitsi P, Lin K, Hamilton G, Daniilidou M, Tsolaki M, et al. The role of ABCA1 gene sequence variants on risk of Alzheimer's disease. J Alzheimers Dis. 2014;38(4):897–906.

37. Hsu W-L, Ma Y-L, Hsieh D-Y, Liu Y-C, Lee EHY. STAT1 Negatively Regulates Spatial

Memory Formation and Mediates the Memory-Impairing Effect of Aβ [Internet]. Vol. 39, Neuropsychopharmacology. 2014. p. 746–58. Available from: http://dx.doi.org/10.1038/npp.2013.263

38. Huang P, Chandra V, Rastinejad F. Retinoic Acid Actions through Mammalian Nuclear Receptors [Internet]. Vol. 114, Chemical Reviews. 2014. p. 233–54. Available from: http://dx.doi.org/10.1021/cr400161b

39. Satoh J-I, Yamamoto Y, Asahina N, Kitano S, Kino Y. RNA-Seq data mining: downregulation of NeuroD6 serves as a possible biomarker for alzheimer's disease brains. Dis Markers. 2014 Dec 8;2014:123165.

40. Mathys H, Davila-Velderrain J, Peng Z, Gao F, Mohammadi S, Young JZ, et al. Single-cell transcriptomic analysis of Alzheimer's disease. Nature. 2019 Jun;570(7761):332–7.

41. Mohammadi S, Davila-Velderrain J, Kellis M. Reconstruction of Cell-type-Specific Interactomes at Single-Cell Resolution. Cell Syst. 2019 Dec 18;9(6):559–68.e4.

42. Ferris HA, Perry RJ, Moreira GV, Shulman GI, Horton JD, Kahn CR. Loss of astrocyte cholesterol synthesis disrupts neuronal function and alters whole-body metabolism. Proc Natl Acad Sci U S A. 2017 Jan 31;114(5):1189–94.

43. Griffiths WJ, Abdel-Khalik J, Yutuc E, Morgan AH, Gilmore I, Hearn T, et al. Cholesterolomics: An update. Anal Biochem. 2017 May 1;524:56–67.

44. Koldamova R, Lefterov I. Role of LXR and ABCA1 in the pathogenesis of Alzheimer's disease - implications for a new therapeutic approach. Curr Alzheimer Res. 2007 Apr;4(2):171–8.

45. Liao F, Yoon H, Kim J. Apolipoprotein E metabolism and functions in brain and its role in Alzheimer's disease. Curr Opin Lipidol. 2017 Feb;28(1):60–7.

46. Kitamura Y, Shimohama S, Ota T, Matsuoka Y, Nomura Y, Taniguchi T. Alteration of transcription factors NF-kappaB and STAT1 in Alzheimer's disease brains. Neurosci Lett. 1997 Nov 14;237(1):17–20.

47. Fowler KD, Funt JM, Artyomov MN, Zeskind B, Kolitz SE, Towfic F. Leveraging existing data sets to generate new insights into Alzheimer's disease biology in specific patient subsets. Sci Rep. 2015 Sep 23;5:14324.

48. Kowalski K, Mulak A. Brain-Gut-Microbiota Axis in Alzheimer's Disease. J Neurogastroenterol Motil. 2019 Jan 31;25(1):48–60.

49. Jiang C, Li G, Huang P, Liu Z, Zhao B. The Gut Microbiota and Alzheimer's Disease. J Alzheimers Dis. 2017;58(1):1–15.

50. Ridlon JM, Harris SC, Bhowmik S, Kang D-J, Hylemon PB. Consequences of bile salt biotransformations by intestinal bacteria. Gut Microbes. 2016;7(1):22–39.

51. Magnúsdóttir S, Heinken A, Kutt L, Ravcheev DA, Bauer E, Noronha A, et al. Generation of genome-scale metabolic reconstructions for 773 members of the human gut microbiota. Nat Biotechnol. 2017 Jan;35(1):81–9.

52. Heinken A, Ravcheev DA, Baldini F, Heirendt L, Fleming RMT, Thiele I. Personalized modeling of the human gut microbiome reveals distinct bile acid deconjugation and biotransformation potential in healthy and IBD individuals [Internet]. bioRxiv. 2017 [cited 2019 Aug 1]. p. 229138. Available from: https://www.biorxiv.org/content/10.1101/229138v1.abstract

53. Marksteiner J, Blasko I, Kemmler G, Koal T, Humpel C. Bile acid quantification of 20 plasma metabolites identifies lithocholic acid as a putative biomarker in Alzheimer's disease. Metabolomics. 2018;14(1):1.

54. Tian Y, Gui W, Koo I, Smith PB, Allman EL, Nichols RG, et al. The microbiome modulating activity of bile acids. Gut Microbes. 2020 Mar 5;1–18.

55. Thiele I, Sahoo S, Heinken A, Heirendt L, Aurich MK, Noronha A, et al. When metabolism meets physiology: Harvey and Harvetta [Internet]. bioRxiv. 2018 [cited 2019 Aug 1]. p. 255885. Available from: https://www.biorxiv.org/content/10.1101/255885v1.abstract

56. Xie G, Wang Y, Wang X, Zhao A, Chen T, Ni Y, et al. Profiling of serum bile acids in a healthy Chinese population using UPLC-MS/MS. J Proteome Res. 2015 Feb 6;14(2):850–9.

57. Xie G, Zhong W, Li H, Li Q, Qiu Y, Zheng X, et al. Alteration of bile acid metabolism in the rat induced by chronic ethanol consumption. FASEB J. 2013 Sep;27(9):3583–93.

58. Wang Y, Eddy JA, Price ND. Reconstruction of genome-scale metabolic models for 126 human tissues using mCADRE. BMC Syst Biol. 2012 Dec 13;6:153.

59. Braissant O, McLin VA, Cudalbu C. Ammonia toxicity to the brain. J Inherit Metab Dis. 2013 Jul;36(4):595–612.

60. Redzic Z. Molecular biology of the blood-brain and the blood-cerebrospinal fluid barriers: similarities and differences. Fluids Barriers CNS. 2011 Jan 18;8(1):3.

61. Pardridge WM. Transport of nutrients and hormones through the blood-brain barrier. Diabetologia. 1981 Mar;20 Suppl:246–54.

62. Pardridge WM, Mietus LJ. Palmitate and cholesterol transport through the blood-brain barrier. J Neurochem. 1980 Feb;34(2):463–6.

63. Spector R. Fatty acid transport through the blood-brain barrier. J Neurochem. 1988 Feb;50(2):639–43.

64. Smith QR. Transport of glutamate and other amino acids at the blood-brain barrier. J Nutr. 2000 Apr;130(4S Suppl):1016S – 22S.

65. Pardridge WM. The blood-brain barrier: bottleneck in brain drug development. NeuroRx. 2005 Jan;2(1):3–14.

66. Uhlén M, Fagerberg L, Hallström BM, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue-based map of the human proteome. Science. 2015 Jan 23;347(6220):1260419.

67. Martín-Jiménez CA, Salazar-Barreto D, Barreto GE, González J. Genome-Scale

Reconstruction of the Human Astrocyte Metabolic Network. Front Aging Neurosci. 2017 Feb 13;9:23.

68. Lewis NE, Schramm G, Bordbar A, Schellenberger J, Andersen MP, Cheng JK, et al. Large-scale in silico modeling of metabolic interactions between cell types in the human brain. Nat Biotechnol. 2010 Dec;28(12):1279–85.

69. Zur H, Ruppin E, Shlomi T. iMAT: an integrative metabolic analysis tool. Bioinformatics. 2010 Dec 15;26(24):3140–2.

70. Gudmundsson S, Thiele I. Computationally efficient flux variability analysis. BMC Bioinformatics. 2010 Sep 29;11:489.

71. Heirendt L, Arreckx S, Pfau T, Mendoza SN, Richelle A, Heinken A, et al. Creation and analysis of biochemical constraint-based models using the COBRA Toolbox v.3.0. Nat Protoc. 2019 Mar;14(3):639–702.

72. Funk CC, Jung S, Richards MA, Rodriguez A, Shannon P, Donovan R, et al. Atlas of Transcription Factor Binding Sites from ENCODE DNase Hypersensitivity Data Across 27 Tissue Types [Internet]. bioRxiv. 2018 [cited 2019 Sep 5]. p. 252023. Available from: https://www.biorxiv.org/content/10.1101/252023v1

73. Zaharia M, Bolosky WJ, Curtis K, Fox A, Patterson D, Shenker S, et al. Faster and More Accurate Sequence Alignment with SNAP [Internet]. arXiv [cs.DS]. 2011. Available from: http://arxiv.org/abs/1111.5572

74. Boyle AP, Guinney J, Crawford GE, Furey TS. F-Seq: a feature density estimator for high-throughput sequence tags. Bioinformatics. 2008 Nov 1;24(21):2537–8.

75. Piper J, Elze MC, Cauchy P, Cockerill PN, Bonifer C, Ott S. Wellington: a novel method for the accurate identification of digital genomic footprints from DNase-seq data. Nucleic Acids Res. 2013 Nov;41(21):e201.

76. Gusmao EG, Dieterich C, Zenke M, Costa IG. Detection of active transcription factor binding sites with the combination of DNase hypersensitivity and histone modifications. Bioinformatics. 2014 Nov 15;30(22):3143–51.

77. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003 Nov;13(11):2498–504.